SCHEMBL118204

SCHEMBL118204

COC(=O)c1ccc(S(=O)(=O)Nc2ncccc2Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
MAPT P10636 2/20 0.52
ALDH1A1 P00352 4/20 0.48
GAA P10253 1/20 0.48
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
RAB9A P51151 2/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
SLC40A1 Q9NP59 1/20 0.46
KDM4E B2RXH2 1/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 1/20 0.44
TCF4 P15884 1/20 0.44
CTNNB1 P35222 1/20 0.44
CYP2C9 P11712 1/20 0.44
FBP1 P09467 1/20 0.44
PLAU P00749 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119812 0.86 SLC7A11 (0.54) TSHRMAPTALDH1A1GAAALOX15
SCHEMBL118688 0.81 FLT1 (0.55) TSHRMAPTALDH1A1GAAALOX15
SCHEMBL120256 0.80 MEN1 (0.54) TSHRMAPTALDH1A1GAAALOX15
SCHEMBL121322 0.79 CCR4 (0.47) TSHRMAPTALDH1A1GAAALOX15
SCHEMBL119695 0.76 MEN1 (0.71) MAPTALDH1A1GAAHTTSMN1; SMN2
SCHEMBL1107257 0.76 TP53 (0.45) TSHRMAPTALDH1A1GAAALOX15
SCHEMBL2301933 0.76 ALDH1A1 (0.67) MAPTALDH1A1GAAHTTSMN1; SMN2
SCHEMBL20598033 0.75 FFAR4 (0.61) TSHRMAPTALDH1A1GAAHTT
SCHEMBL2174600 0.75 FFAR4 (0.61) TSHRMAPTALDH1A1GAAALOX15
SCHEMBL119346 0.75 CYP2C9 (0.51) TSHRMAPTALDH1A1GAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 TSHR 1240/4885MAPT 2242/4885ALDH1A1 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.